Cantor Fitzgerald Forecasts ADMA Biologics FY2025 Earnings

ADMA Biologics, Inc. (NASDAQ:ADMA) – Investment analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for ADMA Biologics in a research note issued on Thursday, March 20th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will post earnings per share of $0.73 for the year, up from their prior estimate of $0.70. Cantor Fitzgerald has a “Overweight” rating and a $25.00 price target on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $19.80 on Friday. ADMA Biologics has a 52-week low of $5.90 and a 52-week high of $23.64. The company has a market cap of $4.68 billion, a P/E ratio of 70.71 and a beta of 0.60. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock’s 50-day simple moving average is $16.76 and its 200 day simple moving average is $18.03.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of ADMA Biologics by 13.9% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 658,900 shares of the biotechnology company’s stock valued at $13,171,000 after buying an additional 80,400 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in ADMA Biologics during the third quarter worth $61,858,000. Raymond James Financial Inc. acquired a new stake in ADMA Biologics in the fourth quarter valued at $19,076,000. EWG Elevate Inc. acquired a new stake in ADMA Biologics in the fourth quarter valued at $480,000. Finally, Citigroup Inc. grew its position in shares of ADMA Biologics by 251.7% in the 3rd quarter. Citigroup Inc. now owns 387,226 shares of the biotechnology company’s stock valued at $7,741,000 after acquiring an additional 277,138 shares during the period. 75.68% of the stock is currently owned by institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.